tiprankstipranks
Alto Neuroscience, Inc. (ANRO)
NYSE:ANRO
US Market

Alto Neuroscience, Inc. (ANRO) Stock Forecast & Price Target

563 Followers
See the Price Targets and Ratings of:

ANRO Analyst Ratings

Strong Buy
10Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Alto
Neuroscience, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ANRO Stock 12 Month Forecast

Average Price Target

$34.88
▲(60.89% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Alto Neuroscience, Inc. in the last 3 months. The average price target is $34.88 with a high forecast of $50.00 and a low forecast of $21.00. The average price target represents a 60.89% change from the last price of $21.68.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","26":"$26","51":"$51","13.5":"$13.5","38.5":"$38.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$34.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,13.5,26,38.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.41,25.455384615384617,27.50076923076923,29.546153846153846,31.591538461538462,33.63692307692308,35.682307692307695,37.72769230769231,39.77307692307693,41.81846153846154,43.863846153846154,45.909230769230774,47.95461538461539,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.41,24.29230769230769,25.174615384615386,26.056923076923077,26.939230769230768,27.821538461538463,28.703846153846154,29.58615384615385,30.46846153846154,31.35076923076923,32.23307692307692,33.11538461538461,33.99769230769231,{"y":34.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.41,23.224615384615383,23.03923076923077,22.853846153846153,22.66846153846154,22.483076923076922,22.29769230769231,22.11230769230769,21.926923076923078,21.74153846153846,21.556153846153848,21.37076923076923,21.185384615384613,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.19,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.81,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.63,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.41,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$50.00Average Price Target$34.88Lowest Price Target$21.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on ANRO
Jefferies
Jefferies
$35
Buy
61.44%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Alto Neuroscience, Inc. (NYSE: ANRO)
Stifel Nicolaus Analyst forecast on ANRO
Stifel Nicolaus
Stifel Nicolaus
$33
Buy
52.21%
Upside
Reiterated
04/02/26
Stifel Nicolaus Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)
Wedbush
$22$21
Hold
-3.14%
Downside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (NYSE: ANRO) and Innovative Eyewear, Inc. (NASDAQ: LUCY)
JonesTrading Analyst forecast on ANRO
JonesTrading
JonesTrading
$49$44
Buy
102.95%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (NASDAQ: JSPR), Alto Neuroscience, Inc. (NYSE: ANRO) and Viridian Therapeutics (NASDAQ: VRDN)
BTIG
$28
Buy
29.15%
Upside
Reiterated
04/02/26
Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK) and Alto Neuroscience, Inc. (NYSE: ANRO)
Robert W. Baird Analyst forecast on ANRO
Robert W. Baird
Robert W. Baird
$41$38
Buy
75.28%
Upside
Reiterated
04/02/26
Alto Neuroscience price target lowered to $38 from $41 at BairdAlto Neuroscience price target lowered to $38 from $41 at Baird
William Blair Analyst forecast on ANRO
William Blair
William Blair
Buy
Reiterated
04/01/26
Pipeline Strength and Key Late-Stage Assets Drive Upside in Alto Neuroscience Despite ALTO-101 Setback
H.C. Wainwright Analyst forecast on ANRO
H.C. Wainwright
H.C. Wainwright
$50
Buy
130.63%
Upside
Reiterated
04/01/26
Alto Neuroscience's ALTO-101 miss doesn't impact thesis, says H.C. WainwrightAlto Neuroscience's ALTO-101 miss doesn't impact thesis, says H.C. Wainwright
Chardan Capital Analyst forecast on ANRO
Chardan Capital
Chardan Capital
$30
Buy
38.38%
Upside
Reiterated
04/01/26
Chardan Capital Remains a Buy on Alto Neuroscience, Inc. (ANRO)
TD Cowen Analyst forecast on ANRO
TD Cowen
TD Cowen
Buy
Reiterated
03/17/26
Alto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile
Wolfe Research Analyst forecast on ANRO
Wolfe Research
Wolfe Research
$15
Buy
-30.81%
Downside
Reiterated
10/20/25
Analysts' Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Glaukos (GKOS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Jefferies Analyst forecast on ANRO
Jefferies
Jefferies
$35
Buy
61.44%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Alto Neuroscience, Inc. (NYSE: ANRO)
Stifel Nicolaus Analyst forecast on ANRO
Stifel Nicolaus
Stifel Nicolaus
$33
Buy
52.21%
Upside
Reiterated
04/02/26
Stifel Nicolaus Keeps Their Buy Rating on Alto Neuroscience, Inc. (ANRO)
Wedbush
$22$21
Hold
-3.14%
Downside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (NYSE: ANRO) and Innovative Eyewear, Inc. (NASDAQ: LUCY)
JonesTrading Analyst forecast on ANRO
JonesTrading
JonesTrading
$49$44
Buy
102.95%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Jasper Therapeutics (NASDAQ: JSPR), Alto Neuroscience, Inc. (NYSE: ANRO) and Viridian Therapeutics (NASDAQ: VRDN)
BTIG
$28
Buy
29.15%
Upside
Reiterated
04/02/26
Analysts Conflicted on These Healthcare Names: Merck & Company (NYSE: MRK) and Alto Neuroscience, Inc. (NYSE: ANRO)
Robert W. Baird Analyst forecast on ANRO
Robert W. Baird
Robert W. Baird
$41$38
Buy
75.28%
Upside
Reiterated
04/02/26
Alto Neuroscience price target lowered to $38 from $41 at BairdAlto Neuroscience price target lowered to $38 from $41 at Baird
William Blair Analyst forecast on ANRO
William Blair
William Blair
Buy
Reiterated
04/01/26
Pipeline Strength and Key Late-Stage Assets Drive Upside in Alto Neuroscience Despite ALTO-101 Setback
H.C. Wainwright Analyst forecast on ANRO
H.C. Wainwright
H.C. Wainwright
$50
Buy
130.63%
Upside
Reiterated
04/01/26
Alto Neuroscience's ALTO-101 miss doesn't impact thesis, says H.C. WainwrightAlto Neuroscience's ALTO-101 miss doesn't impact thesis, says H.C. Wainwright
Chardan Capital Analyst forecast on ANRO
Chardan Capital
Chardan Capital
$30
Buy
38.38%
Upside
Reiterated
04/01/26
Chardan Capital Remains a Buy on Alto Neuroscience, Inc. (ANRO)
TD Cowen Analyst forecast on ANRO
TD Cowen
TD Cowen
Buy
Reiterated
03/17/26
Alto Neuroscience: Advancing Late-Stage CNS Pipeline and Strengthened Balance Sheet Support Favorable Risk-Reward Profile
Wolfe Research Analyst forecast on ANRO
Wolfe Research
Wolfe Research
$15
Buy
-30.81%
Downside
Reiterated
10/20/25
Analysts' Top Healthcare Picks: Alto Neuroscience, Inc. (ANRO), Glaukos (GKOS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alto Neuroscience, Inc.

3 Months
xxx
Success Rate
9/9 ratings generated profit
100%
Average Return
+99.89%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +99.89% per trade.
1 Year
Justin WalshJonesTrading
Success Rate
10/10 ratings generated profit
100%
Average Return
+514.29%
Copying Justin Walsh's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +514.29% per trade.
2 Years
xxx
Success Rate
10/10 ratings generated profit
100%
Average Return
+544.04%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +544.04% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ANRO Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
10
9
4
6
9
Buy
6
2
1
7
10
Hold
1
0
0
1
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
11
5
14
21
In the current month, ANRO has received 19 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ANRO average Analyst price target in the past 3 months is 34.88.
Each month's total comprises the sum of three months' worth of ratings.

ANRO Financial Forecast

ANRO Earnings Forecast

Next quarter’s earnings estimate for ANRO is -$0.54 with a range of -$0.63 to -$0.44. The previous quarter’s EPS was -$0.46. ANRO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ANRO has Performed in-line its overall industry.
Next quarter’s earnings estimate for ANRO is -$0.54 with a range of -$0.63 to -$0.44. The previous quarter’s EPS was -$0.46. ANRO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ANRO has Performed in-line its overall industry.
No data currently available

ANRO Sales Forecast

Next quarter’s sales forecast for ANRO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ANRO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ANRO has Performed in-line its overall industry.
Next quarter’s sales forecast for ANRO is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ANRO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ANRO has Performed in-line its overall industry.

ANRO Stock Forecast FAQ

What is ANRO’s average 12-month price target, according to analysts?
Based on analyst ratings, Alto Neuroscience, Inc.’s 12-month average price target is 34.88.
    What is ANRO’s upside potential, based on the analysts’ average price target?
    Alto Neuroscience, Inc. has 60.89% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ANRO a Buy, Sell or Hold?
          Alto Neuroscience, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Alto Neuroscience, Inc.’s price target?
            The average price target for Alto Neuroscience, Inc. is 34.88. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $50.00 ,the lowest forecast is $21.00. The average price target represents 60.89% Increase from the current price of $21.68.
              What do analysts say about Alto Neuroscience, Inc.?
              Alto Neuroscience, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of ANRO?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.